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ORIGINAL ARTICLEPrevalence of Smqnr and plasmid-mediated quinolone resistance
determinants in clinical isolates of Stenotrophomonas maltophilia from
Japan: novel variants of SmqnrH. Kanamori1,2, H. Yano1, A. Tanouchi1, R. Kakuta1, S. Endo1, S. Ichimura3, M. Ogawa3, M. Shimojima3, S. Inomata1, D. Ozawa1,
T. Aoyagi1, D. J. Weber2 and M. Kaku1
1) Department of Infection Control and Laboratory Diagnostics, Internal Medicine, Tohoku University Graduate School of Medicine, Sendai, Miyagi,
Japan, 2) Division of Infectious Diseases, University of North Carolina School of Medicine, Chapel Hill, NC, United States and 3) Department of Bacteriology,
BML Inc., Kawagoe, Saitama, JapanAbstractStenotrophomonas maltophilia is an important pathogen in healthcare-associated infections. S. maltophilia may contain Smqnr, a quinolone
resistance gene encoding the pentapeptide repeat protein, which confers low-level quinolone resistance upon expression in a
heterologous host. We investigated the prevalence of Smqnr and plasmid-mediated quinolone resistance (PMQR) determinants in
S. maltophilia isolates from Japan. A total of 181 consecutive and nonduplicate clinical isolates of S. maltophilia were collected from four
areas of Japan. The antimicrobial susceptibility proﬁles for these strains were determined. PCR was conducted for Smqnr and PMQR
genes, including qnrA, qnrB, qnrC, qnrS, aac(60)-Ib and qepA. PCR products for Smqnr and aac(60)-Ib were sequenced. For the S. maltophilia
isolates containing Smqnr, pulsed-ﬁeld gel electrophoresis (PFGE) was performed using XbaI. Resistance rates to ceftazidime, levoﬂoxacin,
trimethoprim–sulfamethoxazole, chloramphenicol and minocycline were 67.4%, 6.1%, 17.7%, 8.8% and 0%, respectively. The minimum
inhibitory concentration required to inhibit the growth of 50% and 90% of organisms were 0.5 and 2 mg/L for moxiﬂoxacin but 1 and
4 mg/L for levoﬂoxacin, respectively. Smqnr was detected in 104 of the 181 S. maltophilia isolates (57.5%), and the most frequent was
Smqnr6, followed by Smqnr8 and Smqnr11. Eleven novel variants from Smqnr48 to Smqnr58 were detected. The 24 Smqnr-containing
S. maltophilia isolates were typed by PFGE and divided into 21 unique types. Nine S. maltophilia isolates (5.0%) carried aac(60)-Ib-cr. No
qnr or qepA genes were detected. This study describes a high prevalence of Smqnr and novel variants of Smqnr among S. maltophilia from
Japan. Continuous antimicrobial surveillance and further molecular epidemiological studies on quinolone resistance in S. maltophilia are
needed.
New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases.
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p://dx.doi.org/10.1016/j.nmni.2015.04.009IntroductionIn recent years, hospital infections and outbreaks due to
glucose nonfermenting Gram-negative bacilli such as the
multidrug-resistant Pseudomonas aeruginosa and Acinetobacter
baumannii have become a major concern worldwide. In hospital
environments, Stenotrophomonas maltophilia has been isolated
from tap water, nebulizers, ventilator circuits, contaminated
disinfectants and other locations, and it is an importantEuropean Society of Clinical Microbiology and Infectious Diseases
nses/by-nc-nd/4.0/)
NMNI Kanamori et al. Smqnr and PMQR in S. maltophilia 9opportunistic pathogen causing healthcare-associated infections
[1]. Infections due to S. maltophilia are increasing as a result of
developments in advanced medical treatments such as organ
transplantation, chemotherapy, immunosuppressant drugs,
increased numbers of compromised hosts and the increased
use of broad-spectrum antibiotics. S. maltophilia causes various
infections, including respiratory tract infections (pneumonia and
acute exacerbations of chronic obstructive pulmonary disease);
bacteremia; and infections of urinary tract, skin and soft tissues,
bones and joints and eye [2]. Nosocomial infections have high
mortality, which has been reported to range 12.5% to 41% due
to bacteremia, 40% to 50% due to pneumonia and 39% due to
endocarditis [1,3]. S. maltophilia infections are difﬁcult to treat
because the bacterium may exhibit high-level intrinsic resis-
tance to many antimicrobial agents. Trimethoprim–sulfameth-
oxazole, ticarcillin/clavulanate, and quinolones are used for
treatment of S. maltophilia infections, but resistance to these
antibiotics has been increasingly described [3]. Few studies on
the antimicrobial susceptibility of S. maltophilia have been re-
ported in Japan.
Quinolone resistance is mainly caused by chromosomal
mutations of the quinolone resistance–determining regions in
DNA gyrase and DNA topoisomerase IV, as well as porin al-
terations or overexpression of efﬂux pump systems, resulting in
decreased quinolone accumulation [4–6]. However, a plasmid-
mediated horizontally transferable quinolone resistance gene
encoding a pentapeptide repeat protein (qnr) was discovered in
1998 [7]. Since then, other plasmid-mediated quinolone resis-
tance (PMQR) determinants, including aac(60)-Ib-cr, encoding a
variant aminoglycoside acetyltransferase, and qepA, encoding an
efﬂux pump, have been reported worldwide in clinical isolates
of Enterobacteriaceae [5,6]. Studies of PMQR determinants in
Enterobacteriaceae have been increasing, though PMQR de-
terminants in S. maltophilia remain unclear.
The main mechanism of high-level quinolone resistance in
S. maltophilia is thought to involve overexpression of efﬂux
pumps, in particular SmeDEF, and low permeability of the outer
membrane [8]. Quinolone resistance in S. maltophilia can also
occur as a result of mutations of DNA gyrase and topoisom-
erase genes [2]. Smqnr have been recently identiﬁed in
S. maltophilia as a novel chromosomal quinolone resistance gene
encoding the pentapeptide repeat protein SmQnr. Similar to
PMQR determinants in Enterobacteriaceae, Smqnr confers low-
level quinolone resistance in Escherichia coli and may transmit
quinolone resistance genes to other bacteria [9–11]. There are
few studies on the frequency of Smqnr and PMQR genes in
S. maltophilia. In this study, we investigated the antimicrobial
susceptibility of clinical isolates of S. maltophilia and the preva-
lence of Smqnr and PMQR determinants in S. maltophilia isolates
from Japan.New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on beh
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A total of 181 consecutive and nonduplicate clinical isolates of
S. maltophilia were collected between November 2009 and
March 2010 from four areas of Japan, including 43 isolates from
Hokkaido, 49 from Tokyo, 43 from Osaka and 46 from
Fukuoka. S. maltophilia were identiﬁed using the Microscan
Walkaway System (Siemens Healthcare Diagnostics, Tokyo,
Japan) and the Vitek-2 System (Sysmex-bioMérieux, Tokyo,
Japan). Isolates included 148 from sputum (81.8%), 13 from
nasal and throat swabs (7.2%), eight from urine (4.4%) and 12
from other specimens (6.6%). There were no isolates obtained
from blood cultures in this study. The isolates included 160
(88.4%) from hospitalized patients and 21 (11.6%) from com-
munity patients. Institutional review board approval was not
required for this study according to the research guidelines of
the Japanese government (http://www.niph.go.jp/wadai/
ekigakurinri/guidelines.pdf).
Antimicrobial susceptibility testing
Minimum inhibitory concentrations (MICs) of nine antibiotics,
including piperacillin (range, 0.06–128 mg/L), ceftazidime
(0.06–128 mg/L), imipenem (0.06–128 mg/L), minocycline
(0.06–128 mg/L), amikacin (0.06–128 mg/L), levoﬂoxacin
(0.06–128 mg/L), moxiﬂoxacin (0.06–128 mg/L), trimetho-
prim–sulfamethoxazole (1/19–8/152 mg/L) and chloramphen-
icol (2–128 mg/L) were determined by the broth microdilution
method. Clinical and Laboratory Standards Institute (CLSI)
interpretive criteria were used for each antibacterial agent [12].
Quality control was performed using E. coli American Type
Culture Collection (ATCC) 25922 and E. coli ATCC 35218.
PCR and sequencing of Smqnr and PMQR genes
The primers used to amplify an 811 bp fragment containing the
entire Smqnr coding sequence were as follows: 50-ACACA-
GAACGGCTGGACTGC-30 and 50-TTCAACGACGTG-
GAGCTGT-30 [9,11]. Screening of S. maltophilia isolates for
aac(60)-Ib and PMQR genes, including qnrA, qnrB, qnrC, qnrS and
qepA, was conducted by multiplex PCR ampliﬁcation, as
described previously [13]. PCR products for Smqnr and aac(60)-
Ib were sequenced using ABI BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA) on an
ABI 3730xl Analyzer (Applied Biosystems). Nucleotide and
amino acid sequences were analysed with BLAST (http://blast.
ncbi.nlm.nih.gov/Blast.cgi), Expasy translate tool (http://web.
expasy.org/translate/) and CLUSTALW2.1 (http://www.ddbj.
nig.ac.jp/searches-j.html). If one or more amino acid differed
compared to the previously reported Smqnr sequences inalf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 7, 8–14
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ered to be novel and were named numerically according to qnr
nomenclature [14].
Pulsed-ﬁeld gel electrophoresis
For the 24 S. maltophilia isolates containing Smqnr variants
which were detected from four Japanese areas, pulsed-ﬁeld gel
electrophoresis (PFGE) was performed using XbaI (Takara Bio
Inc., Otsu, Japan). Electrophoresis was performed on a 1%
PFGE agarose gel with a CHEF-DR III system (Bio-Rad Labo-
ratories, Richmond, CA, USA). Electrophoretic patterns were
analysed with GelCompar II version 3.0 (Applied Maths, Kor-
trijik, Belgium). Similarity between two tracks was calculated
using the coefﬁcient of Jaccard and band positions. Cluster
analysis and dendrogram generation were performed by the
unweighted pair group method using arithmetic averages. Iso-
lates with similarity >85% were considered to be within a
cluster [15].
Statistical analysis
Statistical signiﬁcance was evaluated by two-sided chi-square
test or Fisher’s test, according to the sample size. A p value of
<0.05 was considered signiﬁcant.ResultsAntimicrobial susceptibility of S. maltophilia isolates
MICs and susceptibility proﬁle of S. maltophilia for the tested
antimicrobial agents are shown in Table 1. Resistance rates to
ceftazidime, levoﬂoxacin, trimethoprim–sulfamethoxazole and
chloramphenicol were 67.4%, 6.1%, 17.7% and 8.8%, respec-
tively. All isolates were susceptible to minocycline. The MIC
required to inhibit the growth of 50% of organisms (MIC50) of
piperacillin, imipenem and amikacin was 128 mg/L, >128 mg/L
and 128 mg/L, respectively. The MIC50 and MIC required to
inhibit the growth of 90% of organisms (MIC90) of moxiﬂoxacinTABLE 1. Minimum inhibitory concentrations (MICs) and suscept
antimicrobial agents
Antibiotic MIC range (mg/L) MI
Piperacillin 0.06–128 128
Ceftazidime 0.06–128 64
Imipenem 0.06–128 >12
Minocycline 0.06–128 0.2
Amikacin 0.06–128 128
Levoﬂoxacin 0.06–128 1
Moxiﬂoxacin 0.06–128 0.5
Trimethoprim–sulfamethoxazole 1/19–8/152 1/1
Chloramphenicol 2–128 8
MIC50, minimum inhibitory concentration required to inhibit the growth of 50% of organism
organisms.
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ﬂoxacin (1 and 4 mg/L, respectively). Fig. 1 shows a comparison
of susceptibility to levoﬂoxacin and moxiﬂoxacin among
S. maltophilia isolates with or without Smqnr genes. Eight (7.7%)
and three (2.9%) of the 104 Smqnr-positive isolates were
resistant to levoﬂoxacin and moxiﬂoxacin using the resistance
breakpoint of MICs 8 mg/L, while three (3.9%) and three
(3.9%) of the 77 Smqnr-negative isolates were resistant to lev-
oﬂoxacin and moxiﬂoxacin, respectively (p >0.05) for both
levoﬂoxacin and moxiﬂoxacin between Smqnr-positive and
-negative isolates). However, 41 (39.4%) and 20 (19.2%) of the
104 Smqnr-positive isolates were resistant to levoﬂoxacin and
moxiﬂoxacin using the resistance breakpoint of MICs 2 mg/L,
while 17 (22.1%) and seven (9.1%) of the 77 Smqnr-negative
isolates were resistant to levoﬂoxacin and moxiﬂoxacin,
respectively (p 0.0134 for levoﬂoxacin and p >0.05 for moxi-
ﬂoxacin between Smqnr-positive and -negative isolates).
Prevalence of Smqnr and PMQR genes in S. maltophilia
The distribution of Smqnr and PMQR genes for S. maltophilia is
summarized in Table 2. Smqnr was detected in Japan at high
frequencies in clinical isolates of S. maltophilia (57.5%; 104/181
isolates). The Smqnr frequency by region was 69.8% (30/43) in
Hokkaido, 53.1% (26/49) in Tokyo, 46.5% (20/43) in Osaka and
60.9% (28/46) in Fukuoka. The most frequent was Smqnr6
(27.9%, 29/104), followed by Smqnr8 (19.2%, 20/104) and
Smqnr11 (13.5%, 14/104). PMQR determinants were detected
in nine S. maltophilia isolates (5.0%). No S. maltophilia isolates
carried qnrA, qnrB, qnrC, qnrS or qepA. Nine (5.0%) were posi-
tive for aac(60)-Ib, and all of them possessed the -cr variant.
PFGE typing of Smqnr-containing S. maltophilia isolates
Dendrogram and PFGE of XbaI-digested genomic DNA from
24 S. maltophilia with Smqnr are shown in Fig. 2, including 11
isolates with Smqnr6 and 13 isolates with Smqnr11. The 24
Smqnr-containing S. maltophilia isolates were divided into 21
unique PFGE types. Of the 11 Smqnr6-containing S. maltophiliaibility proﬁles of Stenotrophomonas maltophilia for the tested
C50 (mg/L) MIC90 (mg/L) Resistance rate (%)
>128
128 67.4
8 >128
5 1 0
>128
4 6.1
2
9 8/152 17.7
16 8.8
s; MIC90, minimum inhibitory concentration required to inhibit the growth of 90% of
European Society of Clinical Microbiology and Infectious Diseases, NMNI, 7, 8–14
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FIG. 1. Comparison of levoﬂoxacin (A) and moxiﬂoxacin (B) susceptibility among Stenotrophomonas maltophilia isolates with or without Smqnr genes.
Susceptible, 2 mg/L; intermediate, 4 mg/L; resistant, 8 mg/L.
NMNI Kanamori et al. Smqnr and PMQR in S. maltophilia 11isolates, ﬁve isolates were novel, while two isolates from Osaka
and Fukuoka, Tokyo and Osaka, or Fukuoka only clustered
together (SM1, SM5 or SM6). All 13 isolates possessing
Smqnr11 were unique.TABLE 2. Distribution of Smqnr and plasmid-mediated
quinolone resistance (PMQR) genes in 181 clinical isolates of
Stenotrophomonas maltophilia
Gene n %
Smqnr
Smqnr2 5 2.8
Smqnr4 2 1.1
Smqnr6 29 16.0
Smqnr8 20 11.0
Smqnr9 3 1.7
Smqnr11 14 7.7
Smqnr18 1 0.6
Smqnr35 4 2.2
Smqnr37 5 2.8
Smqnr41 4 2.2
Smqnr48 1 0.6
Smqnr49 2 1.1
Smqnr50 1 0.6
Smqnr51 1 0.6
Smqnr52 6 3.3
Smqnr53 1 0.6
Smqnr54 1 0.6
Smqnr55 1 0.6
Smqnr56 1 0.6
Smqnr57 1 0.6
Smqnr58 1 0.6
Total 104 57.5
PMQR genes
qnrA 0 0
qnrB 0 0
qnrC 0 0
qnrS 0 0
qepA 0 0
aac(60)-Ib-cr 9 5.0
Total 9 5.0
New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on beh
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variants
In this study, 11 novel variants of Smqnr were discovered, and
the following nucleotide accession numbers were assigned in
the EMBL/GenBank/DDBJ database: Smqnr48, AB852568;
Smqnr49, AB852569; Smqnr50, AB852570; Smqnr51,
AB852571; Smqnr52, AB852572; Smqnr53, AB852573;
Smqnr54, AB905279; Smqnr55, AB905280; Smqnr56,
AB905281; Smqnr57, AB905282; and Smqnr58, AB905283. The
novel variants were compared to those reported previously:
Smqnr1–Smqnr11 (accession numbers AB430839–AB430843,
AB430845–AB430850); Smqnr12–Smqnr18 (accession
numbers FJ596752–FJ596758); Smqnr19–Smqnr27 (accession
numbers EU681371–EU681373, EU681375, EU681378,
EU681381–EU681382, EU681384–EU681385); Smqnr28–
Smqnr47 (accession numbers HQ874463–HQ874464,
HQ896258–HQ896275). A phylogenetic tree showing the
relationship from Smqnr1 to Smqnr58 is shown in Fig. 3. Dif-
ferences in amino acid sequences between novel variants in this
study and previous variants are as follows: SmQnr48 (55S/T,
194T/A of SmQnr36 ), SmQnr49 (18D/G of SmQnr30),
SmQnr50 (119A/V of SmQnr35), SmQnr51 (20T/H of
SmQnr9), SmQnr52 (72R/H, 203V/M of SmQnr11),
SmQnr53 (67K/E, 146W/G of SmQnr37), SmQnr54
(119A/E, 169V/I of SmQnr11), SmQnr55 (82S/N,
115G/W, 194A/T of SmQnr38), SmQnr56 (6S/F,
57T/A, 82S/N of SmQnr39), SmQnr57 (105S/N,
169V/I of SmQnr11), and SmQnr58 (6S/F, 57T/A,
82S/N, 205Q/X of SmQnr39).alf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 7, 8–14
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
FIG. 2. Dendrogram and pulsed-ﬁeld gel
electrophoresis of XbaI-digested genomic
DNA from 24 Smqnr-containing Steno-
trophomonas maltophilia isolates. A, Hok-
kaido; D, Tokyo; F, Osaka; I, Fukuoka; M,
marker.
12 New Microbes and New Infections, Volume 7 Number C, September 2015 NMNIDiscussionGlobal infectious disease surveillance indicates that resistance
rates for trimethoprim–sulfamethoxazole, ticarcillin–clavulanic
acid, ciproﬂoxacin, levoﬂoxacin and minocycline in S. maltophilia
isolates are less than 4.7%, 16.1%, 40%, 6.5% and 5%, respec-
tively [16]. However, large differences in the susceptibility of
S. maltophilia were seen, depending on the country and/or re-
gion. In our study, resistance to trimethoprim–sulfamethoxa-
zole was approximately 18% in Japan, while it has been
reported to be 8% in the Asia-Paciﬁc region, 10% in Europe,
15% in Turkey, 25% in Taiwan and 27% in Spain [3]. The
resistance rate to levoﬂoxacin in this study was 6.1%, which was
the same as seen in a previous study in China [17]. Although the
percentage of strains resistant to quinolones ranged from
13–96% for ciproﬂoxacin, 3–11% for levoﬂoxacin, 0–46% for
gatiﬂoxacin, 6% for moxiﬂoxacin, 56% for norﬂoxacin and 5%
for oﬂoxacin [3], the levoﬂoxacin resistance rate in this study
showed a higher tendency in a MIC scale than to moxiﬂoxacin.
Furthermore, our resistance rate using a MIC of 2 mg/L for
levoﬂoxacin among Smqnr-positive isolates was signiﬁcantly
higher than that in Smqnr-negative isolates; however, there wasNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceno signiﬁcant difference in levoﬂoxacin resistance rate using a
MIC of 8 mg/L (the same as the CLSI criteria) between iso-
lates with or without Smqnr, although the number of sample
strains tested in this study was small. Little association was seen
between Smqnr presence and high-level quinolone resistance in
S. maltophilia, though Smqnr can provide low-level quinolone
resistance, as described in previous studies [9–11,17]. The role
of Smqnr remains unclear, but the reduced susceptibility may be
associated with the selection of mutants having higher resis-
tance, as described in PMQR determinants [7].
In this study, we identiﬁed 21 different PFGE types among the
24 S. maltophilia Smqnr-containing isolates in Japan. These results
suggest that S. maltophilia Smqnr-containing isolates in Japan are
not a single clone but rather are multiple clones. Superinfection
with S. maltophilia is common, with a reported frequency of
20–40% [3,18], and S. maltophilia may be a reservoir for the
dissemination of quinolone resistance to other bacteria. Thus, it
is necessary to monitor Smqnr genes in Enterobacteriaceae and
other organisms as well as in S. maltophilia.
Smqnr, a chromosome-carried quinolone resistance gene in
S. maltophilia, was ﬁrst reported by Shimizu and colleagues in
2008 [9]. There have been several experimental and epidemi-
ologic studies regarding the mechanism and distribution ofEuropean Society of Clinical Microbiology and Infectious Diseases, NMNI, 7, 8–14
nses/by-nc-nd/4.0/)
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FIG. 3. Phylogenetic analysis of the
relationship of SmQnr1–58. The phylo-
gram was provided by the neighbor-
joining method using ClustalW2.1.
NMNI Kanamori et al. Smqnr and PMQR in S. maltophilia 13Smqnr in clinical isolates of S. maltophilia [9–11,17,19,20].
SmQnr1–11 proteins with 2–6 amino acid alterations were
initially identiﬁed in Japan [9], and subsequent SmQnr variants
were described as follows: SmQnr12–18 in UK [11],
SmQnr19–27 in Spain [10], SmQnr28–47 in China [17] and
SmQnr48–58 in Japan (this study). All 11 novel Smqnr variants
in our study were derived from Smqnr genes reported previ-
ously from Japan and China. Our study suggests a high preva-
lence of Smqnr in S. maltophilia from Japan (Table 2), and thereNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on beh
This is an open access artiwere regional differences of 47–70% in Smqnr frequency. The
most common Smqnr gene in our study was Smqnr6, followed
by Smqnr8 and Smqnr11, while Smqnr8 and Smqnr35 were most
common in China. Further molecular epidemiological studies
investigating the prevalence of Smqnr variants in other countries
are needed.
Unlike Enterobacteriaceae, PMQR determinants in
S. maltophilia have not been fully clariﬁed. A previous study in
China showed that PMQR determinants, including qnrA, qnrB,alf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 7, 8–14
cle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
14 New Microbes and New Infections, Volume 7 Number C, September 2015 NMNIqnrC, qnrD and qnrS, were not detected in S. maltophilia [17]. In
this investigation, we report the detection of aac(60)-Ib-cr in
S. maltophilia, but no qnr or qepA genes were seen. The aac(60)-
Ib-cr gene, which confers resistance to both quinolones and
aminoglycosides, has often been detected in CTX-M-producing
Enterobacteriaceae [6,21] and is a concern for facilitating
further multidrug resistance in S. maltophilia.
In conclusion, our study revealed a high prevalence of Smqnr
among S. maltophilia from Japan and described novel variants of
Smqnr. We also investigated the prevalence of PMQR de-
terminants and demonstrated the presence of aac(60)-Ib-cr genes
in clinical isolates of S. maltophilia. Continuous antimicrobial
surveillance for S. maltophilia and further investigations into
quinolone resistance mechanisms in S. maltophilia are required.Conﬂict of interestNone declared.AcknowledgementSupported by JSPS KAKENHI grant 24790546.References[1] Senol E. Stenotrophomonas maltophilia: the signiﬁcance and role as a
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